Tag Archives: Novartis

Merck KGaA MS Drug on the Fast Track

By George Koroneos | Published: July 28, 2010

Merck KGaA received word July 25 that its application for the multiple sclerosis treatment Cladribine had received priority review status by FDA, decreasing the evaluation period from 10 months to six months, and closing the gap between Merck and the competition. “This is a critical milestone on the path to potential approval for short-course therapy with [...]

Posted in Strategy | Also tagged Cladribine, EMD Serono, Fereydoun Firouz, Food and Drug Administration, Gilenia, Merck KGaA, Merck Serono, Multiple Sclerosis | Leave a comment

Novartis Employees Get $250 million Payout

By Reid Paul | Published: May 19, 2010

A Federal jury in New York ruled against Novartis in a gender discrimination lawsuit, ordering the company to pay $3.36 million in compensatory damages to 12 women and $250 million in punitive damages to 5,600 others in one of the largest gender discrimination class actions in American history. The women charged that Novartis created a [...]

Posted in Corporate Responsibility, Legal, Sales | Also tagged Class-action Suits, Compensatory Damages, Discrimination, Harrassment, Punitive Damages, Sales Reps | Leave a comment

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010

Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]

Posted in Europe, Global, Guest Blog, Strategy | Also tagged AstraZeneca, diagnostics, diversification, GSK, Merck & Co, Schering Plough | Leave a comment

Novartis Names Jimenez CEO

By George Koroneos | Published: January 26, 2010

Novartis shocked investors on Tuesday morning when the Swiss-based firm announced that CEO Daniel Vasella would relinquish his post as CEO to Joe Jimenez while retaining his chairman of the board spot. According to a release, this move has been in the works since 2008 and lead to the restructuring of its management team. The executive [...]

Posted in Strategy | Also tagged AstraZeneca, business, Chief financial officer, Daniel Vasella, Switzerland | 1 Comment

Prix Galien Push for Private/Public Collaboration

By Andrew Sheivachman | Published: October 6, 2009

Preceding the presentation of the 2009 Prix Galien USA prizes, last Tuesday, a round table discussion was conducted at the American Museum of Natural History on the subject of how public and private collaboration can increase innovation and contribute to saving lives around the world. The talk included Leonard Bell of Alexion Pharmaceuticals, Barry Bloom [...]

Posted in Events | Also tagged Africa, American Museum of Natural History, GlaxoSmithKline, Harvard School of Public Health, Jeffrey Sachs, Prix Galien, Public health, United States | Leave a comment